Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc LIFE

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:LIFE)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 8 days ago

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

GlobeNewswire May 15, 2024

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis

GlobeNewswire May 14, 2024

aTyr Pharma to Present at Upcoming Investor Conferences

GlobeNewswire May 6, 2024

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

GlobeNewswire May 2, 2024

aTyr Pharma to Participate in April Investor Conferences

GlobeNewswire April 1, 2024

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

GlobeNewswire March 14, 2024

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

GlobeNewswire February 28, 2024

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT(TM) Clinical Trial Participants

GlobeNewswire February 21, 2024

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity

GlobeNewswire January 29, 2024

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

GlobeNewswire January 18, 2024

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

GlobeNewswire November 13, 2023

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

GlobeNewswire November 9, 2023

aTyr Pharma to Present at November Investor Conferences

GlobeNewswire November 1, 2023

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT(TM) Study of Efzofitimod in Patients with SSc-ILD

GlobeNewswire October 31, 2023

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

GlobeNewswire September 11, 2023

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire August 24, 2023

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

GlobeNewswire August 9, 2023

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Systemic Sclerosis

GlobeNewswire June 22, 2023

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

GlobeNewswire June 20, 2023